Catalog No.
YHE32001
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Val567-Lys734
Predicted molecular weight
21.22 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P41250
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Diadenosine tetraphosphate synthetase, Glycine--tRNA ligase, GlyRS, Glycyl-tRNA synthetase, GARS1, Glycyl-tRNA synthetase 1, Ap4A synthetase, GARS
Glycyl-tRNA sequestration is a unifying mechanism underlying GARS1-associated peripheral neuropathy., PMID:40119731
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer., PMID:39152248
Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D., PMID:38551018
Variants in mitochondrial disease genes are common causes of inherited peripheral neuropathies., PMID:38549004
Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology., PMID:38235113
Glycyl-tRNA Synthetase Induces Psoriasis-Like Skin by Facilitating Skin Inflammation and Vascular Endothelial Cell Angiogenesis., PMID:37827278
Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a potential prognostic and immunotherapeutic biomarker for multiple cancers, including bladder cancer., PMID:37404826
Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice., PMID:36928301
Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro., PMID:36901698
A missense, loss-of-function YARS1 variant in a patient with proximal-predominant motor neuropathy., PMID:36307205
Clinical characteristics and proteome modifications in two Charcot-Marie-Tooth families with the AARS1 Arg326Trp mutation., PMID:35971119
Two distinct receptor-binding domains of human glycyl-tRNA synthetase 1 displayed on extracellular vesicles activate M1 polarization and phagocytic bridging of macrophages to cancer cells., PMID:35523311
Pathogenic missense variants altering codon 336 of GARS1 lead to divergent dominant phenotypes., PMID:35332613
HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell-Based Model of Charcot-Marie-Tooth Disease (Type 2D)., PMID:34958183
Variants of aminoacyl-tRNA synthetase genes in Charcot-Marie-Tooth disease: A Korean cohort study., PMID:34813128
Drosophila Models for Charcot-Marie-Tooth Neuropathy Related to Aminoacyl-tRNA Synthetases., PMID:34680913
Inhibition of GARS1-DT Protects Against Hypoxic Injury in H9C2 Cardiomyocytes via Sponging miR-212-5p., PMID:34483291
Extracellular vesicles derived from macrophages display glycyl-tRNA synthetase 1 and exhibit anti-cancer activity., PMID:33708357
Distal hereditary motor neuropathies: Mutation spectrum and genotype-phenotype correlation., PMID:33369814
Clinical, Genetic, and Disability Profile of Pediatric Distal Hereditary Motor Neuropathy., PMID:33067402
GARS-related disease in infantile spinal muscular atrophy: Implications for diagnosis and treatment., PMID:32181591
For research use only. Not for human or drug use.
